All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Pharmacoeconomic Evaluation on Treatment of Diabetic Patients in a Charitable Hospital

Author(s): Sofia Sunny, C. S. Shastry*, U. V. Mateti, S. Chand1 and R. Sharma1
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, 1Department of General Medicine, Justice K. S. Hegde Charitable Hospital, Nitte (Deemed to be University), Deralakatte, Mangaluru-575 018, India

Correspondence Address:
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, India,E-mail:

This study aimed to conduct a pharmacoeconomic evaluation of the treatment of diabetic patients in a charitable hospital. A retrospective study was carried out for a period of 8 months from August 2016-March 2017. Patients admitted in general medicine with age above 18 years diagnosed with diabetes and on at least one antidiabetic medication. Patient’s data was collected by referring patient’s treatment charts and case notes, hospital billing system, medical record department and hospital pharmacy department. In this study, the direct medical cost was analysed. A total number of 212 diabetic patients were enrolled in the study of which 131 (61.8 %) were males, and 81 (38.2 %) were females. It was found that 67 % of patients had comorbid conditions and 33 % without any complications. One hundred and eleven (52.35 %) patients were prescribed a combination of insulin and oral hypoglycaemic agents, 66 (31.13 %) patients received insulin alone and 35 (16.50 %) patients received only oral hypoglycaemic agents. The annual median cost incurred for the management of diabetes with and without complications per patient was INR 14 959.60 and INR 8619.90, respectively. The study revealed that the costs for males with and without diabetes complications were INR 21 095 and INR 11 644.70, respectively. The corresponding figure for females was INR 12 030 and INR 8515. The cost incurred for nephropathy and peripheral circulatory co-morbidities was the highest (INR 53 795.50), whereas the cost for managing diabetes with nephropathy, neuropathy, retinopathy and peripheral circulatory comorbidities was INR 37 888.00. The study concluded that the cost of treatment could be drastically reduced by early identification and treatment of diabetes thereby preventing the development of diabetes-associated comorbidities.

Full-Text | PDF

Google scholar citation report
Citations : 69022

Indian Journal of Pharmaceutical Sciences received 69022 citations as per google scholar report